APA (7th ed.) Citation

Laban, S., Osinowo, S., Hu, C., Tosiek, M., & Pronk, L. (2025). 1441TiP An open-label, phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852). Annals of Oncology, 36, S874. https://doi.org/10.1016/j.annonc.2025.08.2072

Chicago Style (17th ed.) Citation

Laban, S., S. Osinowo, C. Hu, M. Tosiek, and L.C Pronk. "1441TiP An Open-label, Phase Ib Trial to Assess the Safety and Efficacy of SIRPα Monoclonal Antibody BI 770371 in Combination with Pembrolizumab with or Without Cetuximab Compared with Pembrolizumab Monotherapy for the First-line Treatment of Patients with Head and Neck Squamous Cell Carcinoma (NCT06806852)." Annals of Oncology 36 (2025): S874. https://doi.org/10.1016/j.annonc.2025.08.2072.

MLA (9th ed.) Citation

Laban, S., et al. "1441TiP An Open-label, Phase Ib Trial to Assess the Safety and Efficacy of SIRPα Monoclonal Antibody BI 770371 in Combination with Pembrolizumab with or Without Cetuximab Compared with Pembrolizumab Monotherapy for the First-line Treatment of Patients with Head and Neck Squamous Cell Carcinoma (NCT06806852)." Annals of Oncology, vol. 36, 2025, p. S874, https://doi.org/10.1016/j.annonc.2025.08.2072.